The effect of different concentrations of metformin in the liver and kidney functions for diabatic induced male rats.
Article Sidebar
Main Article Content
Abstract
The aimed of the study to determination the effects of reducing diabetes drug "Metformin" on the liver and kidney function by number of biochemical parameters, including two liver enzymes: Alanine Transaminase (ALT), Alkaline phosphatase (ALP), and concentration of kidney function in the blood serum urea, and uric acid. male albino rats,which were used in this study. The results showed an increase in ALT activity, as well as the status of ALP activity. The concentrations of urea, and uric acid increase significantly (P≤0.05) in serum of rats the animals that were given alloxan compared to the control group. The concentrations of these enzymes decreased in the third and fourth groups of animals that were dosed with metformin at a concentration of 500,850 mg compared with the alloxan group. The group treated with metformin at a concentration of 850 mg was revealed three times the lower activities of all enzymes throughout the study period.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Tikrit Journal of Pure Science is licensed under the Creative Commons Attribution 4.0 International License, which allows users to copy, create extracts, abstracts, and new works from the article, alter and revise the article, and make commercial use of the article (including reuse and/or resale of the article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made, and the licensor is not represented as endorsing the use made of the work. The authors hold the copyright for their published work on the Tikrit J. Pure Sci. website, while Tikrit J. Pure Sci. is responsible for appreciate citation of their work, which is released under CC-BY-4.0, enabling the unrestricted use, distribution, and reproduction of an article in any medium, provided that the original work is properly cited.
References
]1[ NASRI, H.(2013).Renoprotective effects of metformin. DARU,. Pharm Sci, 21 (36): 1-3.
]2[ Ratziu, V.(2016) Novel Pharmacotherapy Options for NASH. Dig Dis Sci 2016;61:1398-405.
]3[ Marchetti, P., Gregorio F, Benzi L, et al.(1990). Diurnal pattern of plasma metformin concentrations and its relation to metabolic effects in type 2 (non-insulin-dependent) diabetic patients. Diabetes Metab 1990;16:473-8.
]4[ Saeedi Saravi, SS, Hasanvand A, Shahkarami K, et al.(2016) The protective potential of metformin against acetaminophen-induced hepatotoxicity in BALB/C mice. Pharm Biol 54:2830-7.
]5[ Amini, F. G.; Rafieian-Kopaei, M.; Nematbakhsh, M.; Baradaran,Nasri, H.(2012) Ameliorative effects of metformin on renal histologic and biochemical alterations of gentamicin-induced renal toxicity in Wistar rats. J. Res. Med . Sci., 17(7):621-5.
]6[ Najeed, S. A., Khan, I. A., Molnar, J., & Somberg, J.C.(2002). Differential effect of glyburide (glibenclamide) and metformin on QT dispersion: A potential adenosine triphosphate sensitive K+ channel effect. The American Journal of Cardiology, 90(10), 1103–1106.
]7[ Curthoys, N. P.(2013). Renal ammonium ion production and excretion.5thed, Seldin and Giebisch’s the kidney.
]8[Rena, G., Pearson, E.R., and Sakamoto, K. (2013). Molecular mechanism of action of metformin: Old or new insights? Diabetologia, 56(9), 1898–1906.
]9[Liu, N., Xu, L., Shi, Y., Fang, L., Gu, H., Wang, H., and Zhuang, S. (2017). Pharmaco-logic targeting ERK1/2 attenuates the development and progression of hyperuri-cemic nephropathy in rats. Oncotarget, 8(20), 33807–33826.
]10[ Perfil’ev, V. Y, Zverev, Y. F, Perfil’eva, D. Y, Lysenko, I. V, & Miroshnichenko, A. G. (2017). Metformin reduces urate nephropathy in experimental nephrolithiasis. Regul Mech Bio, 8(4), 644–648 .
]11[ DeFronzo, R., Fleming, GA., Chen ,MK, Bicsak TA.(2016) Metformin-associated lactic acidosis: Current perspectives on causes and risk. Metabolism. 2016; 65:20–9.
]12[ Peters, N, Jay N, Barraud D, Cravoisy A, Nace L, Bollaert PE, Gibot S.(2008) Metformin-associated lactic acidosis in an intensive care unit. Crit Care. ; 12:R149.
]13[ Salis, A.; Petrson R.; Stecker M.; Patal N.; Willis L.; Galley P.;Eclavea A.and Dreesen R.(2001). Suprarenal Intraarterial infusion of alloxan and streptozotocin during Balloon occlusion of the Juxtrarenal abdominal aorta : A simple technique for inducing Diabetes Mellitus in Canines with reduced mortality. Acad Rad.,8:473 – 477.
]14[ Balucci-Roslido, E.; Sliviro, K.; Gorge, M. and Ganazaga, H. (2001). "Effect of isotretior on tooth
germ of palate development I mouse embryos". Braz. Dent. J. 12(2):115-119-339.
]15[ Tietz, N. W.(2005). "Textbook of clinical chemistry and molecular diagnostics", 4th ed. Burtis CA, Ashwood ER, Bruns DE. WB Saunders.
]16[ Williams, G. Z; Widdowson, G. M. and Penton, J. (1978). Individual character of variation in time series of healthy people II. Differences in values for clinical analysis in serum among demographic groups, by age and sex. Clin. Chem., 24(2):313-320.
]17[ Tietz, N.W. (1986), "Textbook of Clinical Chemistry", W.B. Saunders Company, philadelphia
]18[ Fossati, P. and Prencipe, L. (1982). Serum triglyceride determined colorimetrically with an enzyme that produce hydrogen per-oxide. Clin.Chem; 28(16) 2077-2080.
]19[ Morgan, T.M. and Case, L.D. (2013). Conservative sample size Determination for Repeated Measures Analysis of Covariance. ]20[Yanardag, R., Ozsoy-Sacan, O., Bolkent, S., Orak, H., and Karabulut-Bulan, O. (2005). Protective effects of metformin treatment on the liver injury of streptozotocin-diabetic rats. Human & Exper Toxic, 24(3)129–135. ]21[ Maiti, R., Jana D, Das UK, Ghosh D. (2004) Antidiabetic effect of aqueous extract of seed of Tamarindus indica in streptozotocin-induced diabetic rats. J Ethnopharmacol 2004; 92: 85-91. ]22[ Islam Tanjir, S. Nasrin, M. Rashid, T. Sultana, and Hassan KawsarMd.(2016) "Beneficiary Effect of Combination Therapy of Metformin and Pitavastatin Drug on Alloxan Induced Diabetic Rats Comparing to Single Drug. ]23[ Ntemka, A., Iliadis, F., Papanikolaou, N. A., and Grekas, D. (2011). Network-centric analysis of genetic predisposition in diabetic nephropathy. Hippokratia, 15(3) 232. ]24[ Idonije, B. O., Festus, O., & Oluba, O. M.(2011). Plasma glucose, creatinine and urea levels in type 2 diabetic patients attending a Nigerian teaching hospital. Research journal of medical sciences, 5(1) 1-3. ]25[ Morales-López, H., Rubio-Guerra F, A., K Garro - Almendaro, A., Vargas-Ayala, G., B Duran-Salgado, M., Huerta-Ramírez, S., & J Lozano-Nuevo, J. (2017). Circulating levels of uric acid and risk for metabolic syndrome. Current Diabetes Reviews, 13(1), 87-90.